Atrial Fibrillation set to affect people tremendously in the upcoming years
Urgent action is required to prevent, diagnose and treat atrial fibrillation so as to lower down the increasing rate of heart strokes.
Facts About AFib
- It has been estimated that between 2.9 million and 6.2 million people in the US are suffering from AFib. The number is expected to increase with the increasing population, especially the geriatric population.
- In 2017, AFib was the major cause, leading to 26,077 deaths out of 166,793 deaths
- In 2019, it has been estimated that 1,055,000 coronary events occurred in the U.S. that includes 7, including 20,000 new and 335,000 recurrent coronary events.
Various companies have introduced products to overcome Atrial Fibrillation, for instance,
- In February 2020, CardioFocus, Inc., a medical device company focused on providing an advanced system for ablation treatment for atrial fibrillation (AFib) announced that the company has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for the HeartLight X3 Endoscopic Ablation System for the treatment of AFib
- In November 2019, Biosense Webster EMEA, a Division of Johnson & Johnson Medical NV/SA and leading manufacturer in the treatment of Atrial Fibrillation (AF) has confirmed its commitment for undertaking the new millennium epidemic by launching two major initiatives to coincide with Global AF Aware Week, 18-24 November 2019
- In November 2019, The Bristol-Myers Squibb-Pfizer Alliance announced the initiation of a new randomized, controlled study, GUARD-AF (Reducing stroke by screening for UndiAgnosed atrial fibrillation in elderly individuals).